CN115381803B

CN115381803B - Retinoid compositions and uses thereof

Info

Publication number: CN115381803B
Application number: CN202211212681.9A
Authority: CN
Inventors: 杨正茂; 吴哲青; 魏维
Original assignee: Shenzhen Purui Health Technology Co ltd
Current assignee: Shenzhen Purui Health Technology Co ltd
Priority date: 2022-09-30
Filing date: 2022-09-30
Publication date: 2023-09-15
Anticipated expiration: 2042-09-30
Also published as: CN115381803A

Abstract

The application discloses a retinoid composition and application thereof. In the present application, the retinoid composition comprises teprenone and phytol. The retinoid composition provided by the application can effectively reduce the level of inflammatory factors, has good anti-inflammatory effect, and has excellent anti-aging, anti-melanin, anti-radiation and dermis fiber repairing capabilities.

Description

Retinoid compositions and uses thereof

Technical Field

The application relates to the field of external preparations, in particular to a retinoid composition and application thereof.

Background

Skin inflammation is a common symptom of inflamed skin caused by, for example, exposure to ultraviolet radiation, ionizing radiation, allergens, chemical irritants, biostimulants, or mechanical injury. This skin inflammation (also known as "acute" inflammation) is a complex process and is a response to helping the skin resist infection. Derivatives of vitamin a such as phytoretinol have an effect of promoting cell differentiation by acting on keratinocytes and increasing collagen production and elasticity, and increasing skin elasticity and inhibiting wrinkle formation by inhibiting keratinization, have been widely used as active ingredients of external preparations and have been used for treating skin diseases such as acne, psoriasis and keratinocytes. However, although such retinoids have been found to have an anti-inflammatory function on skin, the inventors have found in research that a single class of retinoids has very limited efficacy in reducing the release of the inflammatory factors IL-1 beta, TNF-alpha and down-regulating the p38MAPK and NF-kB signaling pathways, blocking inflammatory responses. And long-term use may destroy skin barrier, enhance oxidative stress of skin, cause skin relaxation and melanin production. Thus, there is a need in the art to actively study the formulation of retinoids or derivatives thereof that have better anti-inflammatory effects and less side effects.

Disclosure of Invention

The object of the present application is to provide a retinoid composition.

Another object of the present application is to provide an external preparation composition containing the above retinoid composition.

It is a further object of the present application to provide the use of the retinoid composition described above.

To solve the above technical problem, a first aspect of the present application provides a retinoid composition, which includes: teprenone and phytol.

In some preferred embodiments, the retinoid composition also includes a vehicle for dissolving the teprenone and the phytol.

In some preferred embodiments, the ratio of the mass percentages of the teprenone and the phytol is (2.5-3.5): 4.5-5.5, e.g. 3:5.

In some preferred embodiments, the retinoid composition consists of the following ingredients:

teprenone … … in 2.5-3.5 weight portions;

… … 4.5.5-5.5 parts by weight of phytol.

… … 3 parts by weight of teprenone;

… … 5 parts by weight of phytol.

In a second aspect of the present application, there is provided an external preparation composition comprising the retinoid composition according to the first aspect of the present application and an external preparation acceptable adjuvant.

In some preferred embodiments, the topical acceptable excipients include humectants, surfactants, and preservatives.

In some preferred embodiments, the pharmaceutically acceptable excipients for the external preparation further comprise antioxidants and anti-inflammatory agents.

In some preferred embodiments, the humectant is selected from at least one, more preferably at least two, of propylene glycol and glycerin.

In some preferred embodiments, the surfactant is selected from at least one of GTCC caprylic/capric triglyceride, isooctyl palmitate, montanov 68, simusol 165, and sepipplus 400, polydimethylsiloxane, more preferably at least two, more preferably at least three, more preferably at least four, more preferably at least five, more preferably all six.

In some preferred embodiments, the anti-inflammatory agent comprises dipotassium glycyrrhizinate.

In a third aspect of the present application there is provided the use of a retinoid composition provided in the first aspect of the application for:

(i) Increasing thioredoxin expression levels;

(ii) Elevating the expression level of RAR and/or RXR;

(iii) Increasing the expression level of collagen and/or elastin;

(iv) Elevating the expression level of the peroxidase;

(v) Reducing the expression level of heat shock protein;

(vi) Inhibiting bacterial cell numbers;

(vii) Repairing skin damage; and/or

(viii) The external preparation with the functions of resisting aging, inflammation, allergy, melanin, radiation, bacteria and/or repairing skin injury is prepared.

Compared with the prior art, the application has at least the following advantages:

the retinoid composition provided by the application can effectively reduce the level of inflammatory factors, has good anti-inflammatory effect, and has excellent anti-aging, anti-melanin, anti-radiation and dermis fiber repairing capabilities.

It is understood that within the scope of the present application, the above-described technical features of the present application and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.

Drawings

One or more embodiments are illustrated by way of example and not limitation in the figures of the accompanying drawings.

FIG. 1 is a graph showing the results of immunoblotting of rat hepatocyte thioredoxin content in accordance with the examples of the present application;

FIG. 2 is a schematic representation of the correlation between retinoid compositions and expression levels of RAR and RXR in accordance with an embodiment of the application;

FIG. 3 is a schematic representation of the correlation between retinoid compositions and collagen and elastin expression levels in accordance with an embodiment of the application;

FIG. 4 is a schematic representation of the correlation between retinoid compositions and catalase activity in accordance with an embodiment of the present application;

FIG. 5 is a schematic representation of the correlation between retinoid compositions and HSP27 expression levels in accordance with examples of the present application;

FIG. 6 is a schematic representation of the correlation between retinoid compositions and HSP70 levels in accordance with an embodiment of the present application;

FIG. 7 is a schematic representation of the anti-melanin capacity of a retinoid combination and a conventional whitening agent in accordance with an embodiment of the present application;

FIG. 8 is a schematic representation of the correlation between retinoid compositions and inflammatory factor IL-1. Beta. Levels in an embodiment according to the application;

FIG. 9 is a schematic representation of the correlation between retinoid compositions and inflammatory factor TNF- α levels in an embodiment according to the application;

FIG. 10 is a schematic of the effect of retinoid compositions on viable cell number in an embodiment according to the application;

FIG. 11 is a schematic of the ability of a retinoid composition to repair skin lesions, in accordance with an embodiment of the present application.

Detailed Description

Retinoids have certain anti-wrinkle and anti-inflammatory effects, but they are highly irritating to the skin and cause damage to the skin barrier after long-term use, so the retinoids are generally contained in the external preparations in low amounts. However, at low levels, the anti-wrinkle and anti-inflammatory effects of retinoids are extremely weak or even ineffective. The inventor unexpectedly found that when two plant retinol components of teprenone and phytol are matched for use, the two components can produce synergistic effect, thereby improving the anti-wrinkle and anti-inflammatory effects. Based on this, the present application relates to a retinoid composition comprising: teprenone and phytol. In addition, the inventor also discovers that the retinoid composition containing two plant retinoids of teprenone and phytol also has the effects of resisting melanin, resisting bacteria, repairing skin injury and the like.

Retinoid compositions

One aspect of the present application relates to a retinoid composition comprising: teprenone and phytol.

As used herein, the term "Teprenone (Teprenone)", also known as pentarenone, CAS number: 6809-52-5.

The structural formula is shown as the following formula I.

As used herein, the term "phytol" is also known as phytantriol, a chain diterpenoid oxygen-containing compound, an unsaturated primary alcohol, CAS:74563-64-7. The structural formula is shown as the following formula II.

In a preferred embodiment of the present application, a vehicle for dissolving the teprenone and the phytol, which is a solvent commonly used in the field of external preparations, such as soybean oil, is also included in the retinoid composition.

The retinoid composition of the application is prepared from the teprenone and the phytol in a solvent. The retinoid composition of the application can be used as concentrated essence to be directly applied to skin, and can also be used as a component to be matched with other external preparation auxiliary materials. When applied directly to the skin, in a preferred embodiment of the application, the teprenone comprises 3% to 5% by mass of the total mass of the retinoid composition; the mass of the phytol accounts for 5% -8% of the total mass of the retinoid composition. The lower content reduces the stimulation to the skin barrier and does not weaken the effects of anti-inflammation, anti-wrinkle and the like.

In order to enhance the synergistic effect of teprenone and phytol, in a preferred embodiment of the present application, the mass percentage ratio of teprenone to phytol is (2.5-3.5): (4.5-5.5), for example, 3:5. Within this ratio range, the two work synergistically optimally, yielding the best anti-inflammatory effect.

In some embodiments of the application, the retinoid composition consists of the following ingredients:

teprenone … … in 2.5-3.5 weight portions;

… … 4.5.5-5.5 parts by weight of phytol.

External preparation composition containing retinoid composition

In the present application, the external preparation includes a retinoid composition, and an acceptable adjuvant in the external preparation.

As acceptable adjuvants in external preparations, it may be selected from solvents, solubilizers, preservatives, antioxidants, pH adjusters, permeation promoters, liposomes, moisturizers, thickeners, chelators, skin feel modifiers, surfactants, emulsifiers, propellants/propellants, fragrances, pigments, and other efficacy additives. For example, in one embodiment of the present application, the acceptable excipients in the external preparation are moisturizers, surfactants, anti-inflammatory agents, and preservatives.

The mass percentage of the composition is 0.1 to 99% relative to the total mass of the external preparation; preferably 1 to 90%; more preferably 1 to 90%; more preferably 1 to 80%; more preferably 1 to 70%; more preferably 1 to 60%; more preferably 1 to 50%; more preferably 1 to 30%; more preferably 1 to 15%; more preferably 1 to 10%; more preferably 1 to 9%; more preferably 1 to 7%; more preferably 1 to 6%; more preferably 1 to 5%, for example: 2%, 3%, 4% or 5%. Particularly preferred in the present application, the composition is 1 to 5% by mass.

As the preservative, it may be selected from, but not limited to, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, benzoate, sorbic acid, triclosan, triclocarban, etc.), metal chelating agents. Agents (e.g., EDTA, NTA, etc.), proteolytic enzymes, preservatives (zincpyrythion, octropix, etc.), permeation promoters (benzyl alcohol, benzyl oxyethanol, etc.), thickeners (carboxyvinyl polymers, etc.), may contain carboxymethyl cellulose, polyvinyl alcohol, carrageenan, water-soluble polymers such as gelatin, electrolytes, pH adjusters (buffers such as sodium lactate and citrate-sodium citrate).

The amount of the preservative to be added to the external preparation of the present application is preferably 0.01 to 50% by weight (hereinafter, abbreviated as "wt%), and particularly preferably 0.5 to 20%.

As the humectant, it is possible to select, without limitation, glycerin, ceramide or its like structural substance, cholesterol ester, sorbitol, xylitol, glycerin, martitol, propylene glycol, 1, 3-butylene glycol, etc., and examples thereof include at least one of 1, 4-butylene glycol, sodium pyrrolidone carboxylate, lactic acid, sodium lactate, polyoxypropylene fatty acid ester, polyethylene glycol, etc. Particularly preferred humectants in the present application are glycerin and propylene glycol.

The amount of the humectant to be added to the external preparation of the present application is preferably 0.01 to 50% by weight (hereinafter simply referred to as "wt%), and particularly preferably 0.5 to 20%.

As anti-inflammatory agents, it is possible to select from, without limitation, methyl salicylate, ethylene salicylate, indomethacin, ibuprofen, allantoin, lysozyme chloride, guaiac, gamma-coumarin, tocopheryl acetate, glycyrrhizic acid, dipotassium glycyrrhizinate, glycyrrhetinic acid and salts thereof. These may be used singly or in combination of two or more. Particularly preferred in the present application, the anti-inflammatory agent is dipotassium glycyrrhizinate.

The amount of the antiinflammatory agent to be added to the external preparation of the present application is preferably 0.001 to 5%, particularly preferably 0.1 to 2%.

As the surfactant, caprylic/capric triglyceride, isooctyl palmitate, polydimethylsiloxane, cetostearyl glucoside/cetostearyl alcohol, glyceryl stearate/PEG-100 stearate, polyacrylic acid 13/polyisobutylene/polysorbate-20, etc., may be mentioned without limitation, and particularly preferably, the surfactant is a combination of GTCC caprylic/capric triglyceride, isooctyl palmitate, montanov 68, simusol 165 and SEPIPLUS 400, polydimethylsiloxane in the present application.

The amount of the surfactant to be added to the external preparation of the present application is preferably 1 to 50%, particularly preferably 10 to 30%.

In the most preferred embodiment of the present application, the external preparation composition is made of the components: 5g of GTCC caprylic/capric triglyceride, 3g of isooctyl palmitate, 1g of polydimethylsiloxane (viscosity 100 model), 3g of teprenone, 5g of phytol, 2g of Montanov 68 (cetostearyl glucoside/cetostearyl alcohol), 1g of Simosol 165 (glyceryl stearate/PEG-100 stearate), 0.1g of dipotassium glycyrrhizinate, 3g of propylene glycol, 3g of glycerol, 1g of SEPIPLUS 400 (polyacrylic acid 13/polyisobutylene/polysorbate-20), 1g of preservative and 71.9g of water.

The term "external preparation" as used in the present application means a chemical industrial product or fine chemical product which is spread on any part of the surface of a human body such as skin, hair, nails, lips and teeth, etc. by applying, spraying or the like to achieve cleaning, maintenance, beauty, modification and change of appearance, or to correct odor of a human body, with the aim of maintaining a good state. In a preferred embodiment of the present application, the external preparation comprises: a moisturizing external preparation, an anti-inflammatory external preparation with moisturizing effect and an anti-aging or whitening external preparation with moisturizing effect.

The topical formulations should be applied periodically topically to any area of skin that requires treatment with the frequency and amount necessary to achieve the desired result. Preferably, the topical formulation is administered at least once daily, most preferably twice daily. The frequency of treatment depends on the extent of skin damage or deterioration, the reactivity of the user's skin, the concentration of the active ingredient in the external preparation, the effectiveness of the carrier used to transport the active ingredient into the stratum corneum, the convenience of removing the article by physical contact with clothing or by perspiration or other internal or external liquids, and the convenience to the user's type. Typical concentrations of relatively simple biochemically active materials such as the topical formulations described herein may range from about 0.01% to about 5.0% by weight, based upon the total weight of the topical formulation, and the formulation should be applied to the skin in a ratio of from about 1.0mg/cm2 of skin to about 20.0mg/cm2 of skin. Preferably, the formulation should contain from about 0.39% to about 0.78% based on the total weight of the topical formulation composition. Most preferably, the formulation should contain about 0.78% active ingredient and be applied to the skin at a rate of about 5.0mg/cm2 of skin.

The effects of the external preparations of the present application include, but are not limited to: anti-inflammatory, antibacterial, antiaging, melanin-resisting, and skin injury repairing effects.

Use of retinoid compositions

The application also relates to the use of a retinoid composition for:

(i) Increasing thioredoxin expression levels;

(ii) Elevating the expression level of RAR and/or RXR;

(iii) Increasing the expression level of collagen and/or elastin;

(iv) Elevating the expression level of the peroxidase;

(v) Reducing the expression level of heat shock protein;

(vi) Inhibiting bacterial cell numbers;

(vii) Repairing skin damage; and/or

The present application will be further described with reference to specific embodiments in order to make the objects, technical solutions and advantages of the embodiments of the present application more apparent. It is to be understood that these examples are illustrative of the present application and are not intended to limit the scope of the present application. The experimental methods, in which specific conditions are not noted in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated. The experimental materials and reagents used in the following examples were obtained from commercial sources unless otherwise specified.

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs, it is to be noted that the terms used herein are used merely to describe specific embodiments and are not intended to limit exemplary embodiments of the application.

Example 1 retinoid compositions

The following components are mixed in proportion to prepare the retinoid composition:

3g of Teprenone (Teprenone); phytol (Phytol) 5g.

Example 2 external preparation composition

Each 100g of the composition is prepared from the following components: 5g of GTCC caprylic/capric triglyceride, 3g of isooctyl palmitate, 1g of polydimethylsiloxane (viscosity 100 model), 3g of teprenone, 5g of phytol, 2g of Montanov 68 (cetostearyl glucoside/cetostearyl alcohol), 1g of Simosol 165 (glyceryl stearate/PEG-100 stearate), 0.1g of dipotassium glycyrrhizinate, 3g of propylene glycol, 3g of glycerol, 1g of SEPIPLUS 400 (polyacrylic acid 13/polyisobutylene/polysorbate-20), 1g of preservative and 71.9g of water.

Example 3 retinoid compositions

2.5g of Teprenone (Teprenone); phytol (Phytol) 5.5g.

Example 4 retinoid compositions

3.5g of Teprenone (Teprenone); phytol (Phytol) 4.5g.

Example 5 enhancement of expression level of thioredoxin

Thioredoxin is widely present in both prokaryotic and eukaryotic organisms, regulates the redox balance of the organism by reducing the protein of interest, repairs oxidative damage to the organism by reducing the disulfide bonds oxidized in the cells, and prevents aging of the organism through this pathway.

Experiment group 1: 1mg of a retinoid composition (teprenone 3 g+phytol 5 g) is applied;

experiment group 2: applying 1mg of teprenone;

experiment group 3: 1mg of phytol was applied:

control group: no product was applied.

Thioredoxin induction was performed on cultured rat hepatocytes and the amount of rat hepatocytes thioredoxins was determined by immunoblotting using an antibody against mouse thioredoxin.

As shown in FIG. 1, the experimental groups all increased the accumulation of thioredoxin compared to the control group, and the experimental group 1 was most remarkable, indicating that the retinoid composition prepared in example 1 had excellent anti-aging ability.

Example 6 upregulation of RAR and RXR expression levels

RAR and RXR are important targets for retinoids and play an important role in cell growth, differentiation and organogenesis.

experiment group 2: applying 1mg of teprenone;

experiment group 3: 1mg of phytol was applied:

control group: no product was applied.

The cultured human fibroblasts were placed in 4 dishes, and after culturing for 48 hours after 1mg of the retinoid composition was applied to experimental group 1, mRNA expression was measured by Northern blot. The same method was used to treat experimental groups 2, 3 and control groups to determine mRNA expression.

As shown in fig. 2, experimental group 1 can significantly up-regulate the expression of RAR and RXR compared to the other groups.

Example 7 promotion of collagen and elastin expression

Collagen is a main structural protein composing skin, and elastin is a kind of fibrin, which can activate fibroblast to avoid skin aging and relaxation.

experiment group 2: applying 1mg of teprenone;

experiment group 3: 1mg of phytol was applied:

control group: no product was applied.

The cultured human fibroblasts were placed in 4 dishes, 1mg of the retinoid composition was applied as in experiment group 1, and after culturing for 24 hours, the collagen and elastin contents were determined. The same method was used to treat experimental groups 2, 3 and control groups to determine the collagen and elastin content.

As shown in fig. 3, experimental group 1 significantly increased the content of collagen and elastin compared to the other groups.

Example 8 anti-free radical and increased catalase Activity

Catalase can delay cell senescence by reducing oxidative stress

experiment group 2: applying 1mg of teprenone;

experiment group 3: 1mg of phytol was applied:

control group: no product was applied.

The cultured human fibroblasts were placed in 4 dishes, and after culturing for 48 hours by applying 1mg of the retinoid composition in the manner of experimental group 1, the catalase activity was determined from the lysate of the cultured cells by an enzymatic reaction. The same method was used to treat the experimental groups 2, 3 and the control group to determine the activity of catalase.

As shown in fig. 4, experimental group 1 was able to significantly increase catalase activity compared to the other groups.

Example 9 protection of cells against UV radiation

Heat Shock Proteins (HSPs) are cytoprotective proteins that aid in the proper folding of protein structures, thereby preserving their activity. When the body is stimulated by high temperature, radiation and the like, the expression of HSP is increased, and the HSP is one of the most main regulatory proteins in cells. HSP27 and HSP70 are chaperones, and under UV irradiation, proteins are significantly overexpressed.

experiment group 2: applying 1mg of teprenone;

experiment group 3: 1mg of phytol was applied:

control group: no product was applied.

The positive cell numbers of HSP27 and HSP70 were measured 24 hours after application of 1mg retinoid composition to skin explant sections in a semi-quantitative manner under different conditions of UVB irradiation. The same method was used to treat experimental groups 2, 3 and control groups to measure the number of positive cells of HSP27 and HSP 70.

As shown in fig. 5 and 6, the expression of HSP27 and HSP70 was reduced in experimental group 1 as compared with the other groups.

Example 10 anti-melanin

In this example, the anti-melanin ability of the retinol combination and the conventional whitening agent of the present application was tested.

The specific experimental steps are as follows: B16F10 mice were cultured under a-MSH stimulation, and 7 parts of the culture were divided into no (control group), 12.5mg of the retinoid composition (experimental group 1), 25mg of the retinoid composition, 50mg of arbutin, 5mg of kojic acid, and 50mg of resveratrol, and the culture was performed for 24 hours. The B16F10 mouse melanoma cells were washed with PBS, the cells harvested by centrifugation were lysed in 1N NaOH heavy containing 10% dmso, and the mixture sonicated and incubated for 30 min at 80 ℃. The melanin content was determined by measuring absorbance at 475nm using a microplate reader.

As shown in fig. 7, the inhibition of melanin by the application of retinoid compositions was dose-dependent. And under the same concentration, the anti-melanin effect is obviously better than that of arbutin, kojic acid and resveratrol.

EXAMPLE 13 reduction of inflammatory factor Release from IL-1 beta, TNF-alpha and the like

experiment group 2: applying 1mg of teprenone;

experiment group 3: 1mg of phytol was applied:

control group: no product was applied.

The cultured human fibroblasts were placed in 4 dishes, 1mg of the retinoid composition was applied, and after culturing for 48 hours, the IL-1. Beta. And TNF-alpha content were measured. The same method was used for treating experimental groups 2, 3 and control groups, and measuring the content of IL-1 beta and TNF-alpha.

As shown in fig. 8 and 9, compared with the other groups, the experimental group 1 can remarkably reduce the release of inflammatory factors such as IL-1 beta, TNF-alpha and the like, and simultaneously down regulate p38MAPK and NF-kB signaling pathways, and reduce the body inflammation phenomenon.

Example 14 inhibition of S.aureus FDA209P cell number

This example demonstrates the ability of the retinoid compositions prepared in example 1, the retinoid solutions of comparative examples 1, 2 to inhibit the number of s.aureus FDA209P cells. The overnight culture from S.aureus FDA209P was washed twice with PBS, the cell pellet was suspended in 1ml of PBS, 100. Mu.L was aliquoted in 10ml of buffer containing the retinoid composition, teprenone phytol, respectively, and the mixture was incubated at 37 ℃. After 0, 2, 4, 6, 8, 10, 12 hours, samples were taken to determine the number of living cells.

As shown in FIG. 10, the retinoid composition showed increased inhibition of S.aureus FDA209P cell numbers over time and was more potent than teprenone and phytol.

Example 15 repair of dermal fibers

Climatic stress, particularly in cold and dry weather, can cause skin damage, significantly destroying the dermal matrix fibers. The retinoid composition prepared in example 1 (a mixture of teprenone and phytol) was tested in the present application for its ability to repair skin lesions. The method comprises the following specific steps: the effect of retinoid compositions on climate change was evaluated by using reconstructed skin models. The skin model was subjected to short-term daily climatic stress and repeated 3 times in summer conditions (high temperature: 40 ℃,80% relative humidity) for 30 minutes; in winter conditions (cold and dry: 10 ℃,40% relative humidity), 15 minutes and 3 times over 36 hours. The normal environment is normal temperature (25 ℃,50% relative humidity). The skin model was stained with hematoxylin-eosin.

As shown in fig. 11, climatic stress, particularly cold and dry weather, causes 3D skin damage. These lesions can be prevented after the use of the retinoid composition, and the skin structure morphology remains unchanged.

It will be understood by those of ordinary skill in the art that the foregoing embodiments are specific examples of carrying out the application and that various changes in form and details may be made therein without departing from the spirit and scope of the application.

Claims

1. A retinoid composition, wherein the retinoid composition consists of:

2.5-3.5 parts by weight of teprenone;

4.5 to 5.5 parts by weight of phytol.

2. The retinoid composition according to claim 1, characterized in that it consists of the following components:

3 parts by weight of teprenone;

5 parts by weight of phytol.

3. An external preparation composition, wherein the external preparation composition comprises the retinoid composition according to any one of claims 1 or 2 and auxiliary materials acceptable in external preparations.

4. The external preparation composition according to claim 3, wherein the external preparation acceptable auxiliary materials include a humectant, a surfactant and a preservative.

5. The composition according to claim 4, wherein the auxiliary acceptable for external preparation further comprises an antioxidant and an anti-inflammatory agent.

6. The composition according to claim 5, wherein the humectant is at least one selected from propylene glycol and glycerin;

and/or the surfactant is selected from at least one of GTCC caprylic/capric triglyceride, isooctyl palmitate, montanov 68, simosol 165, SEPIPLUS 400 and polydimethylsiloxane.

7. Use of a retinoid composition according to any one of claims 1 or 2 for:

preparing external preparation with antiaging and/or skin injury repairing effects.